GO
Loading...

Pharmaceuticals

More

  • Dec 17- Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs. "We believe the price reflects the significant clinical, economic and humanistic value of the product to patients and the healthcare system,...

  • Arrests made in 2012 meningitis outbreak Wednesday, 17 Dec 2014 | 8:46 AM ET

    Federal authorities arrested 14 people related to a Massachusetts pharmacy connected to a deadly 2012 outbreak of fungal meningitis.

  • Novartis sues India's Cipla over respiratory drug Onbrez Wednesday, 17 Dec 2014 | 8:22 AM ET

    MUMBAI, Dec 17- Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price. Cipla, India's fourth-largest drugmaker by revenue, launched its copy of Onbrez in New Delhi in October, citing urgent unmet need for the...

  • Lethal injection drug bill clears Ohio Legislature Wednesday, 17 Dec 2014 | 2:08 AM ET

    COLUMBUS, Ohio— The names of companies that provide Ohio with lethal injection drugs would be shielded under a proposal the state House is poised to vote on Wednesday. Problems finding supplies of lethal drugs have created a de facto moratorium on executions in Ohio, which a decade ago was one of the country's busiest death penalty states. Ohio executed just one...

  • SINGAPORE, Dec 17- Business sentiment among Asia's top companies rose in the fourth quarter with builders switching to most optimistic from least just three months earlier due in part to increased new orders, while property developers also showed a rise in sentiment. The Thomson Reuters/ INSEAD Asian Business Sentiment Index rose to 72 in the fourth quarter, up...

  • Eli Lilly bumps up dividend for first time since 2009 Tuesday, 16 Dec 2014 | 10:44 AM ET

    INDIANAPOLIS— Shares of Eli Lilly outpaced broader trading indexes Tuesday morning, a day after the drugmaker announced its first dividend increase in more than five years. That will raise the quarterly payout to 50 cents per share, or $2 annually. Eli Lilly and Co. shares climbed about 1 percent, or 71 cents, to $70.38 Tuesday, while the Standard& Poor's 500 index...

  • Judge halts Alzheimer's drug swap until July Monday, 15 Dec 2014 | 5:27 PM ET

    District Judge Robert Sweet told Dublin- based Actavis PLC to continue making the drug Namenda available for 30 days after generic alternatives become available on July 11 "in order to allow for an orderly transition." His injunction orders the company to inform doctors and pharmacists of the decision and tells Actavis not to impose any hurdles for filling...

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • ZURICH, Dec 12- Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson& Johnson's Stelara. The data follows results last year showing Cosentyx, also known as secukinumab, was superior to Amgen's Embrel in a head-to-head study. Other drugmakers working on new...

  • TEL AVIV, Dec 11- Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta...

  • Ohio senators pass lethal injection drug bill Thursday, 11 Dec 2014 | 1:26 AM ET

    COLUMBUS, Ohio— Ohio is weighing changes to its lethal injection law that are meant to restart executions, but the updated law will undoubtedly lead to lawsuits that will make carrying out the next scheduled procedure on Feb. 11 impossible, a prosecutor said Thursday. The Summit County prosecutor's office is not counting on Ronald Phillips' execution happening,...

  • Dec 10- Walgreen Co said Chief Executive Greg Wasson would retire and hand the reins on an interim basis to the head of Alliance Boots Holdings Ltd, a move that follows a series of events that has tested investor confidence in the U.S. drugstore chain. Walgreen said Wasson would step down shortly after it completes the purchase of the 55 percent it does not already...

  • New HPV vaccine strengthens cancer protection Wednesday, 10 Dec 2014 | 3:22 PM ET

    WASHINGTON— The drugmaker Merck& Co. Inc. has received approval for an updated version of its Gardasil vaccine that protects against an additional five strains of the virus that causes most cases of cervical cancer. The FDA said Wednesday the updated Gardasil has the potential to prevent roughly 90 percent of cervical, vulvar, vaginal and anal cancers.

  • Merck advancing breast cancer drug to mid-stage Wednesday, 10 Dec 2014 | 12:54 PM ET

    TRENTON, N.J.— Drugmaker Merck& Co. said Wednesday that it will advance a new cancer drug into bigger patient tests, after promising findings in an early study against a very aggressive, common type of breast cancer. Merck, based in Kenilworth, New Jersey, said it will start mid-stage patient tests of Keytruda in the first half of 2015. It's received accelerated...

  • Arca's potential Ebola drug gets "orphan drug status" Wednesday, 10 Dec 2014 | 11:19 AM ET

    Dec 10- Arca Biopharma Inc said the U.S. Food and Drug Administration granted its experimental drug orphan drug status as a potential treatment for viral hemorrhagic fever after exposure to the Ebola virus. The Westminster, Colorado- based company, whose stock rose about 11 percent on Wednesday, joins a list of drugmakers looking for ways to fight the largest...

  • Ohio lawmakers debate execution drugmaker bill Wednesday, 10 Dec 2014 | 9:28 AM ET

    COLUMBUS, Ohio— Companies providing Ohio with lethal injection drugs would have their names shielded for at least 20 years, under a bill scheduled for a possible vote that lawmakers say is needed to restart executions in the state. Ohio hasn't executed an inmate since January, when Dennis McGuire gasped and snorted for 26 minutes before dying, during a procedure...

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • CHICAGO, Dec 9- The U.S. Department of Health and Human Services on Tuesday offered liability protections to drugmakers rushing to develop Ebola vaccines and urged other countries to follow suit. Health and Human Services Secretary Sylvia Burwell made the announcement as part of the Public Readiness and Emergency Preparedness Act in a move aimed at...

  • Merck committed to Cubist after patent losses Tuesday, 9 Dec 2014 | 9:29 AM ET

    Merck remains committed to its $8.4 billion acquisition of Cubist Pharmaceuticals even though a federal court invalidated most of the patents protecting the company's top-selling antibiotic just hours after that deal was announced Monday. The court upheld one patent that would stave off a cheaper generic version of the drug from rival Hospira Inc. until...

  • Valeant to drop deal-making to cut debt, lift stock Tuesday, 9 Dec 2014 | 9:00 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Valeant Pharmaceuticals is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt and boost its stock price.